A randomised trial of sirolimus- versus paclitaxel-coated balloons for de novo coronary lesions
EuroIntervention · 2024-11 · 20 (21) · e1322-e1329
DOI: 10.4244/eij-d-23-00868 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift EuroIntervention, 2024-11. Verfasst von Bruno Scheller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Experimental Interventional Cardiology, University of Saarland, Saarbrücken, Germany. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Coronary, Coronary Artery Disease, Paclitaxel, Sirolimus. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Paclitaxel-coated balloons (PCB) are a viable alternative to drug-eluting stents in the treatment of de novo coronary lesions. Whether sirolimus represents an alternative to paclitaxel for drug-coated balloons remains elusive. AIMS: This randomised, controlled, multicentre, non-inferiority trial investigated a novel sirolimus-coated balloon (SCB) with a crystalline coating versus a PCB in de novo coronary lesions. METHODS: To compare a novel SCB with a clinically proven PCB, 70 patients with de novo coronary lesions were enrolled at 4 centres in Germany and Switzerland. The primary endpoint was non-inferiority regarding angiographic late lumen loss (LLL) at 6 months, with a predefined margin of δ=0.35 mm. Secondary endpoints included procedural success, major adverse cardiac events, and individual clinical endpoints. RESULTS: Quantitative coronary angiography revealed no differences in baseline parameters. At 6 months, in-segment LLL was 0.04±0.39 mm in the PCB group versus 0.11±0.37 mm in the SCB group (non-significant), respectively. The mean difference between SCB and PCB was 0.07 mm (95% confidence interval: -0.12 to 0.26). Non-inferiority at the predefined margin of 0.35 was shown. Clinical event rates up to 12 months were not different between the groups (3 target lesion revascularisations in the PCB group versus 2 in the SCB group, no myocardial infarctions, no deaths). CONCLUSIONS: The novel SCB showed similar angiographic outcomes in the treatment of de novo coronary disease as compared with a clinically proven PCB (ClinicalTrials.gov: NCT03908450).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical and Experimental Interventional Cardiology, University of Saarland, Saarbrücken, Germany.
- University Hospital of Saarland, Homburg/Saar, Germany.
- Department of Internal Medicine and Cardiology, Heart Center Dresden, Technische Universität Dresden, Dresden, Germany.
- University Hospital Basel, University of Basel, Basel, Switzerland.
- Triemli Hospital, Zürich, Switzerland.
- Protestant Hospital Paul Gerhardt Stift, Lutherstadt Wittenberg, Germany.
Zitieren
APA
Scheller, B., Mangner, N., Jeger, R. V., Afan, S., Mahfoud, F., Woitek, F. J., Fahrni, G., Schwenke, C., Schnorr, B., & Kleber, F. (2024). A randomised trial of sirolimus- versus paclitaxel-coated balloons for de novo coronary lesions. EuroIntervention, 20(21), e1322-e1329. https://doi.org/10.4244/eij-d-23-00868
Vancouver
Scheller B, Mangner N, Jeger RV, Afan S, Mahfoud F, Woitek FJ, et al. A randomised trial of sirolimus- versus paclitaxel-coated balloons for de novo coronary lesions. EuroIntervention. 2024;20(21):e1322-e1329. doi:10.4244/eij-d-23-00868
BibTeX
@article{Scheller2024,
author = {Scheller, Bruno and Mangner, Norman and Jeger, Raban V and Afan, Samuel and Mahfoud, Felix and Woitek, Felix J and Fahrni, Gregor and Schwenke, Carsten and Schnorr, Beatrix and Kleber, Franz},
title = {A randomised trial of sirolimus- versus paclitaxel-coated balloons for de novo coronary lesions},
journal = {EuroIntervention},
year = {2024},
volume = {20},
number = {21},
pages = {e1322--e1329},
doi = {10.4244/eij-d-23-00868}
}
EUVIMED